Exscientia

Exscientia is an AI-driven precision medicine company at the forefront of revolutionizing drug discovery and development. Founded in 2012 and headquartered in Oxford, UK, Exscientia is committed to discovering, designing, and developing the best possible drugs in the fastest and most effective manner. The company has achieved several milestones, including developing the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study. Exscientia's AI-driven drug discovery platform is used to create precision-engineered, patient-centric therapeutic candidates, with the company being the first to have an AI-designed molecule enter clinical trials. Their internal pipeline focuses on leveraging their precision medicine platform in oncology, while their partnered pipeline broadens their approach to other therapeutic areas. Exscientia's innovative approach combines AI with traditional drug discovery expertise, aiming to make the process of medicine creation faster, more efficient, and more likely to succeed. The company's products, including AI-designed molecules like GTAEXS617 and EXS4318, are primarily used in the healthcare industry, specifically in preclinical drug discovery. Exscientia has established numerous partnerships with pharmaceutical companies and research institutions to apply its technology across various therapeutic areas. In 2024, the company entered into significant agreements, including a merger with Recursion and an acquisition of GT Apeiron's share of its oral CDK7 inhibitor program, further solidifying its position as a leader in AI-driven pharmaceutical research and development.